Want to see TSE:VM full AI Analyst Report?
Top Page
Voyageur Pharmaceuticals
(VM)
Select Model
Select Model
Rating:51Neutral
Price Target:
C$0.14
▼(-17.06% Downside)
Action:Reiterated
Date:07/04/26
The score is held back primarily by weak financial performance—deep losses, negative margins, and ongoing cash burn—despite low leverage. Technicals are a key positive with a clear uptrend and positive momentum, but valuation remains constrained by unprofitability and the absence of a dividend yield.
Positive Factors
Low financial leverage
Low debt relative to equity provides durable financial flexibility, reducing immediate solvency risk and lowering fixed financing costs. This cushion helps sustain R&D and commercialization efforts during an extended development phase and improves options for raising capital on favorable terms if needed.
Negative Factors
Deep unprofitability and negative margins
Deep negative gross profit and large operating losses reflect structural margin problems: current revenue scale is insufficient to cover fixed and processing costs. Persisting unprofitability erodes reserves and makes sustainable margins dependent on meaningful scale-up or cost transformation, a long-duration execution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Low financial leverage
Low debt relative to equity provides durable financial flexibility, reducing immediate solvency risk and lowering fixed financing costs. This cushion helps sustain R&D and commercialization efforts during an extended development phase and improves options for raising capital on favorable terms if needed.
Read all positive factors
Voyageur Pharmaceuticals (VM) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$23.33M
Dividend YieldN/A
Average Volume (3M)72.03K
Price to Earnings (P/E)―
Beta (1Y)-0.56
Revenue GrowthN/A
EPS Growth-28.29%
CountryCA
Employees49
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.02
Shares Outstanding179,475,860
10 Day Avg. Volume61,621
30 Day Avg. Volume72,034
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)21.82
Price to Sales (P/S)2339.21
P/FCF Ratio-9.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Voyageur Pharmaceuticals Business Overview & Revenue Model
Company Description
Voyageur Pharmaceuticals Ltd. specializes in the creation of mineral-based active pharmaceutical ingredients (APIs). The company aims to produce radiocontrast agents utilizing barium and iodine, along with pharmaceutical products derived from brom...
How the Company Makes Money
Revenue model and key streams are not publicly available in sufficient detail to describe factually. null...
Voyageur Pharmaceuticals Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
52
Neutral
Cash Flow
12
Very Negative
| Breakdown | Feb 2026 | Feb 2025 | Feb 2024 | Feb 2023 | Feb 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 11.69K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.22M | -1.57K | -2.19K | -2.91K | -2.25K |
| EBITDA | -3.53M | -1.71M | -1.22M | -1.75M | -2.05M |
| Net Income | -3.53M | -1.71M | -1.40M | -1.75M | -2.05M |
Balance Sheet | |||||
| Total Assets | 3.11M | 2.60M | 2.16M | 2.10M | 2.57M |
| Cash, Cash Equivalents and Short-Term Investments | 267.05K | 165.57K | 2.08K | 31.56K | 812.97K |
| Total Debt | 40.00K | 40.00K | 40.00K | 25.52K | 42.08K |
| Total Liabilities | 1.85M | 2.15M | 727.88K | 630.83K | 660.64K |
| Stockholders Equity | 1.25M | 449.96K | 1.44M | 1.46M | 1.91M |
Cash Flow | |||||
| Free Cash Flow | -2.89M | -302.29K | -991.25K | -2.00M | -2.09M |
| Operating Cash Flow | -2.89M | -302.29K | -991.25K | -1.72M | -1.65M |
| Investing Cash Flow | -270.02K | -165.96K | -174.72K | -274.15K | -432.08K |
| Financing Cash Flow | 3.26M | 631.73K | 1.14M | 1.21M | 2.90M |
Voyageur Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | C$27.62M | -3.14 | -19.10% | ― | 0.66% | -14.29% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | C$23.33M | -6.67 | -256.01% | ― | ― | -28.29% | |
48 Neutral | C$13.29M | -2.99 | ― | ― | -25.05% | 67.74% | |
46 Neutral | C$30.23M | -24.32 | 7.78% | ― | 16.45% | -6.36% | |
44 Neutral | C$15.75M | -5.12 | -71.80% | ― | -17.50% | -120.67% | |
41 Neutral | C$16.35M | -4.25 | -68.32% | ― | 1.96% | -24.60% |
* Healthcare Sector Average
TSE:VM
Voyageur Pharmaceuticals
0.14
-0.13
-48.15%
TSE:LABS
MediPharm Labs
0.07
<0.01
7.69%
TSE:PCLO
PharmaCielo
0.08
0.02
36.36%
TSE:ROMJ
Rubicon Organics
0.46
-0.04
-9.00%
TSE:AVCN
Avicanna
0.12
-0.14
-52.94%
TSE:INNO
InnoCan Pharma
3.50
-11.45
-76.59%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.